U.S. Biosimilars Market Revenue Outlook (2024–2032)

The U.S. Biosimilars Market continued to advance rapidly in ***, driven by expanding therapeutic adoption, increasing biologic patent expirations, and strong regulatory support for interchangeable biosimilars. Market revenue was recorded at USD ***.*** million in *** and is projected to reach USD ***.*** million by ***, reflecting the country’s accelerated shift toward cost-efficient biologic alternatives. Growth is further supported by expanding oncology and immunology portfolios, broader payer acceptance, and improved formulary access across hospital and retail channels. As leading manufacturers scale production, invest in next-generation biosimilar pipelines, and strengthen distribution partnerships, the U.S. maintains its position as one of the fastest-growing global biosimilars markets. Increasing competition, strategic pricing, and continued FDA approvals will continue to shape market performance throughout the forecast period.